

Submitted: 26/01/2022

Accepted: 10/08/2022

Published: 10/09/2022

Influence of genistein and diadizine on regularity of estrous cycle in cyclic female Wistar rat: interaction with estradiol receptors and vascular endothelial growth factor

Doaa H. Elsayed^{1*}, Seham A. Helmy^{2,3}, Amina A. Dessouki⁴, Amal M. El-Nahla⁵,
Heba M. A. Abdelrazek⁵ and Heba Nageh Gad El-Hak⁶

¹Department of Theriogenology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt

²Department of Nursing, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia

³Department of Cytology and Histology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt

⁴Department of Pathology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt

⁵Department of Physiology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt

⁶Department of Zoology, Faculty of Sciences, Suez Canal University, Ismailia, Egypt

Abstract

Background: Isoflavones are estrogenic compounds that exist in soy, clover, and peanuts. They are selective estrogen receptor modulators.

Aim: The study was planned to explain the interactions of isoflavones with estrogen receptors alpha (ER α), beta (ER β), and vascular endothelial growth factor (VEGF) expressions in ovarian and uterine tissues during different stages of the estrous cycle of regular cyclic female Wistar rats.

Methods: Thirty-two regular cyclic females were divided equally into control group: fed casein-based diet and isoflavones group: fed casein-based diet and gavaged 50 mg/kg/day soy isoflavones extract 40%. The regularity of estrus cycles was monitored. Final body weight (FBW), weight gain (BWG), and ovarian and uterine weights were estimated. Histopathology and immunohistochemistry for ER α , ER β , and VEGF in ovarian and uterine tissues were performed.

Results: All females (100%, $n = 16$) in control group showed regularity in estrous cycle compared to 62.5% ($n = 10$) in isoflavones group. Estrus and diestrus phases revealed prolongation and shortening in isoflavones rats than control, respectively. Nonsignificant variation was noted in the duration of the whole cycle of both groups. FBW and BWG significantly decreased however, ovarian and uterine weights increased significantly in all estrous phases of isoflavones group than control. Histopathology demonstrated an increase in number of follicles/ovaries besides, hyperplasia and proliferation of luminal epithelium with hydropic degeneration in the isoflavones group. Also, uterine connective tissue stroma showed edema in the isoflavones group during all estrous phases. Immunostaining percentages of ER α , ER β , and VEGF protein expression were significantly elevated in the isoflavones group during all estrous phases.

Conclusion: Isoflavones induced irregularity of the estrous cycle that was encountered by increased and altered ER α , ER β , and VEGF expressions in ovarian and uterine tissues.

Keywords: ER α , ER β , Estrous cycle, Isoflavones, VEGF.

Introduction

In females, reproductive capacity is monitored by adjusted reproductive physiology associated with balanced hormonal production, the capability of gametogenesis as well as the morphological and biochemical alterations of the ovary and uterus (Rajan *et al.*, 2017). The estrous cycle is characterized by morphological modifications in ovaries, uterus, and vagina (Goldman *et al.*, 2007). Female rats have a short duration of estrous cycle ranging from 4 to 5 days. Estrous cycle is judged by steroid hormones such as

estrogen and progesterone. Estrogen performs its action via binding to estrogen receptors (ERs) and initiating gene expression (da Silva Pacheco *et al.*, 2019). There are two main types of ERs: alpha (ER α) and beta (ER β). These receptors are extensively spread throughout the reproductive system (Kim and Greenwald, 1987). Selective estrogen receptor modulators (SERMs) are group of nonsteroidal compounds that are capable to bind to ERs prompting alterations in the biological activity of receptors (Xu *et al.*, 2017). In a tissue-specific manner, SERMs proceed with their activities as either agonist or antagonist actions on ERs (Xu *et*

*Corresponding Author: Doaa H. Elsayed. Department of Theriogenology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. Email: maryam_mohamed2001@yahoo.com

Articles published in Open Veterinary Journal are licensed under a Creative Commons Attribution-NonCommercial 4.0

al., 2017). That depends on the involvement of ER signaling which includes the distribution of ERs in different tissues (Wang *et al.*, 2000), ligand binding specificity (Kuiper *et al.*, 1997), and varied interactions with coactivators (Webb *et al.*, 2003).

Soy isoflavones are polyphenolic compounds that own a chemical structure analogous to that of estrogen that allows it to bind to nuclear ERs either α and/or β (Franco *et al.*, 2020). Once it binds to ERs, induces receptor-dependent transcription (Morito *et al.*, 2001) by interacting with the estrogen-response element (Patisaul, 2017). Then prompts as an estrogen agonist or antagonist to regulate cell growth, proliferation, and development in the target tissue (Wu *et al.*, 2019). Hence, the biological impacts of isoflavonoids are differed in proportion to the female biological phase (Mc Rodrigues *et al.*, 2018). They also could impair the development of the female genitalia of rodents causing infertility (Nikaido *et al.*, 2004) and implantation losses (Elsayed *et al.*, 2020). Moreover, they were documented to disturb the ovarian function, reduce conception rate as well as upset pregnancy in sheep and cows (Kallela *et al.*, 1984; Adams, 1995). Genistein and daidzein are dominant bioactive members of isoflavones (Šošić-Jurjević *et al.*, 2019). They have antioxidant (Ungar *et al.*, 2003), anti-inflammatory (Wang *et al.*, 2019), and anticancer (Stubert and Gerber, 2009) effects. Isoflavones are thought to be SERMs as they can act with the two subtypes of ERs (Abdelrazek *et al.*, 2019).

Vascular endothelial growth factor (VEGF) is an angiogenic factor that promotes vascular permeability (Patel, 2018) and manages the endometrial endothelial cell proliferation (Danastas *et al.*, 2019). It performs its angiogenic role by binding to two tyrosine kinase receptors: VEGFR1 and VEGFR2 which are expressed on the surface of endothelial cells (Terman *et al.*, 1992). It has strong influence on reproductive tract function. It was implicated in implantation (Elsayed *et al.*, 2020), pregnancy (Tousen *et al.*, 2006) as well as cyclic changes (Rimoldi *et al.*, 2007). The influence of soy isoflavones on uterine and ovarian VEGF is debatable, whereas, some studies denoted that they could impede ovarian and uterine VEGF expression (Elsayed *et al.*, 2020). Other studies had shown that isoflavones up-regulate VEGF expression in ovary or uterus (Helmy *et al.*, 2014; Jarić *et al.*, 2018). Moreover, endometrial proliferation, hyperplasia, and neoplasms are common consequences of the uterine ERs up-regulation. Therefore, the elevation

of the VEGF expression could be related to endometrial proliferation and neoplasia (Kazi *et al.*, 2005; Newbold *et al.*, 2007; Jarić *et al.*, 2018).

The scarcity of literature described the mechanism of isoflavones in cyclic females during the different phases of the estrous cycle. Therefore, this study was designed to elucidate the interactions of isoflavones with ER α , ER β , and VEGF expressions in ovarian and uterine tissues during different stages of estrous cycle of regular cyclic female Wistar rats with special emphasis on their influence on reproductive cycle regularity.

Material and Methods

Animals

A total of 40 mature female Wistar rats (4.5–5 months; 200–220 g) were used in the study. Animals were purchased from Lab Animal House, Faculty of Sciences, Suez Canal University, Ismailia, Egypt. Rats were housed in plastic cages; five females per cage. They were kept at room temperature ($25^{\circ}\text{C} \pm 1^{\circ}\text{C}$) and natural daylight rhythm. Food and water were offered *ad libitum*. Rats were adapted for 2 weeks before the beginning of the experiment. Animals were fed with a casein-based diet.

Reproductive procedures

After 2 weeks of acclimatization, the estrous cycle was monitored by daily cytological examination of vaginal smear according to Singletary *et al.* (2005). Vaginal smears were obtained daily from each female rat early in the morning. Females with two successive regular cycles were selected for this study, while those of irregular cycles were excluded.

Experimental design

Only 32 females exhibited a regular estrous cycle. Regular cyclic rats were divided equally into two groups; G1: control group ($n = 16$) that fed casein-based diet and G2: isoflavones group ($n = 16$) that fed casein-based diet and gavaged 50 mg/kg/day soy isoflavones extract 40% (JMS Vitamins, USA) was dissolved in carboxymethylcellulose with ultrapure water. Each g contained 436 mg isoflavones 132 mg/g genistein and 304 mg/g daidzein that were tested by high-performance liquid chromatography (Elsayed *et al.*, 2020).

Estrous regularity

Vaginal smears were taken from each rat 8 hours apart to determine the average length/hours for each phase of the estrous cycle for three consecutive cycles. Also,

Table 1. Total estrous cycle duration (hours) and different estrous phases (hours).

| Estrous phases | Control | Isoflavones |
|---------------------|-------------------------------|-------------------------------|
| Proestrus | 12.00 \pm 0.54 | 12.00 \pm 0.36 |
| Estrus | 16.75 \pm 1.40 | 48.00 \pm 4.38 ^a |
| Metestrus | 11.25 \pm 0.42 | 10.75 \pm 0.69 |
| Diestrus | 37.50 \pm 1.68 ^a | 30.00 \pm 2.89 |
| Total estrous cycle | 77.50 \pm 2.10 | 88.75 \pm 5.68 |

^aAt the same raw indicates significance at $p < 0.05$

the regularity of estrous cycle was monitored for each experimental female.

Body weight, relative ovarian and uterine weights

Body weights were estimated daily. Weight gain (BWG) was also obtained by subtracting the final weight from the initial weight for each experimental animal. After 30 days of treatment, each female rat was sacrificed after exposing it to 5 ml tetrahydrofuran inhalation (98%, Carlo Erba Reagent Co., Italy) in a desiccator. The ovaries and uteri were dissected from each rat. The relative ovarian and uterine weights were recorded by assessment of the weights of ovaries and uteri per gram about body weight.

Histopathology

The dissected ovaries and uteri were immersed in 10% neutral buffer formalin saline. Afterward, they were processed and stained by hematoxylin and eosin (Slaoui and Fiette, 2011).

Immunohistochemistry (IHC) and image analysis

Paraffin-embedded ovaries and uteri were subjected to 5 µm sections used for the IHC of ERα, Erβ, and

VEGF as stated by Elsayed *et al.* (2020). The primary antibodies used from Thermo Scientific Co., (UK) with catalog numbers; # MA1-16629, # RB- 10658-R7, and # MS-750-R7, respectively. The concentrations were 1:50, 1:10, and 1:100, respectively. Image analysis for IHC stained area percentage (ISAP) was done using the Image J program. In all the slides of both groups, nine random fields per slide were randomly selected.

Statistical analysis

Graphpad prism software (version 7, San Diego, CA) was applied for statistical analysis of the variations between control and soy isoflavones groups in different estrous phases using the Student's *t*-test. All the data within the study were expressed as mean ± SEM. Significance was distinguished at a probability value < 0.05.

Ethical approval

All animals were treated and sampled in accordance with the guidelines for care and use of animals which were approved by the research ethics committee in the




Fig. 1. Body weight (g) and BWG (g) of control and isoflavones cyclic female Wistar rats.

Table 2. Relative ovarian (g) and uterine weights (g) of control and isoflavones groups.

| Parameters | Isoflavones | Control | Estrous phases |
|-------------------------|--------------------------|-------------|----------------|
| Relative ovarian weight | 0.07 ± 0.00 ^a | 0.05 ± 0.00 | Proestrus |
| | 0.07 ± 0.00 ^a | 0.05 ± 0.00 | Estrus |
| | 0.06 ± 0.00 ^a | 0.05 ± 0.00 | Metestrus |
| | 0.07 ± 0.00 ^a | 0.05 ± 0.00 | Diestrus |
| Relative uterine weight | 0.44 ± 0.02 ^a | 0.30 ± 0.02 | Proestrus |
| | 0.45 ± 0.02 ^a | 0.24 ± 0.02 | Estrus |
| | 0.27 ± 0.00 ^a | 0.18 ± 0.00 | Metestrus |
| | 0.19 ± 0.00 ^a | 0.13 ± 0.00 | Diestrus |

^aAt the same raw indicates significance at *p* < 0.01




Fig. 2. (A) Photomicrographs in ovary of control and isoflavones groups in cyclic female Wistar rats: ovarian sections showed increased vascularity specially in estrus and metestrus stages (arrows) along with increased number of follicles (arrowhead) in 50 mg/kg/day isoflavones treated group. The figure was stained by H&E (bar 100 µm). (B) Photomicrograph sections in uterus of control and isoflavones groups in cyclic female Wistar rats: uterus sections showed hyperplasia and proliferation of LE with hydropic degeneration (red arrows) of epithelium in estrus phase of 50 mg/kg/day isoflavones treated group. Uterine stromal edema (asterisk) was evident in isoflavones treated groups during all phases of estrous cycle. The figure was stained by H&E (bar 50 µm).

Faculty of Veterinary Medicine, Suez Canal University (approved no: 2021004 on 27/01/2021).

Results

Regularity of estrous cycles

All females in the control group (100%) showed regularity of estrous cycles. However, 10 (62.5%) out of 16 females in isoflavones group revealed regular estrous cycles. Isoflavones-treated females exhibited significant ($p < 0.0001$) prolongation in the duration of estrus phase rather than control. However, the diestrus phase demonstrated significant ($p < 0.05$) shortening in isoflavones treated rats as compared to control. The proestrus and metestrus durations were nonsignificantly varied between groups. Also, the duration of the whole cycle exhibited a nonsignificant difference between groups (Table 1).

Body weight, relative ovarian and uterine weights

Soy isoflavones group revealed significant ($p < 0.001$) decrease in the final body weight (FBW) and BWG as compared with control group (Fig. 1). However, the relative ovarian and uterine weights in the different estrous phases showed highly significant ($p < 0.01$) increase in soy isoflavones group as compared to control (Table 2).

Ovarian and uterine histopathology

Ovary and uterus of control group showed normal histological details related to each phase of estrous. Administration of isoflavones resulted in increment of ovarian and uterine vascularity, especially in estrus and metestrus phases. The number of follicles/ovaries seemed to increase in isoflavones treated group. The estrus phase of isoflavones treated group revealed hyperplasia and proliferation of luminal epithelium




Fig. 3. (A) Photomicrographs of ovarian sections of ER α immunostaining of cyclic female Wistar rats in control and isoflavones groups: positive intracytoplasmic and intranuclear immunoreactivity was pronounced in 50 mg/kg/day isoflavones group in all phases of estrous cycle as compared to control group. The figure was stained by H&E (bar 100 μ m). (B) Photomicrographs of uterine sections of ER α immunostaining of cyclic female Wistar rats in control and isoflavones groups: intense intracytoplasmic and intranuclear immunoreactivity was demonstrated in the lining epithelium LE and GE of 50 mg/kg/day isoflavones group rather than control group. The figure was stained by H&E (bar 50 μ m).

(LE) with epithelial hydropic degeneration. Moreover, uterine connective tissue stroma exhibited marked edema in isoflavones treated groups during all phases of estrous cycle (Fig. 2).

Immunohistochemistry

The immunostaining of ER α and ER β were demonstrated as brownish intracytoplasmic as well as intranuclear reactions in ovarian and uterine tissues (Figs. 3 and 4). Ovarian ER α was expressed in the stroma; however, ovarian ER β was evident in the stroma and corpora lutea of control group. Isoflavones group expressed ER β in the stroma, corpora lutea and ovarian follicles. Moreover, both receptors were expressed in uterine LE, glandular epithelium (GE), connective tissue stroma (Ct), myometrium (M) and surface epithelium (SE). The ISAP of both ER α and ER β exhibited significant ($p < 0.001$) elevations in isoflavones treated group than control during all phases of the estrous cycle (Table 3).

The immunostaining of VEGF appeared as brownish intra-cytoplasmic reaction in uterine and ovarian tissues (Fig. 5). The VEGF was expressed in the ovarian stroma as well as corpora lutea. The uterine VEGF signals existed in the cytoplasm of LE, GE, Ct, M, SE, and endothelium of blood vessels (v). The ISAP of VEGF exhibited significant ($p < 0.001$) elevations in isoflavones treated group than control during all phases of the estrous cycle (Table 3).

Discussion

The effect of isoflavones, as endocrine-disrupting hazard, on the outcome of rodent reproductive performance is controversial (Patisaul, 2017). Isoflavones including; genistein and daidzein are abundant in human and animal diets (Gaffer *et al.*, 2018). Despite the increasing number of studies, there is still a long way to a firm knowledge on the biological potency of dietary isoflavones and their impact on reproduction, especially in mature cyclic females. In




Fig. 4. (A) Photomicrographs of ovarian sections of ER β immunostaining in control and isoflavones cyclic female Wistar rats: isoflavones group (50 mg/kg/day) showed marked positive intracytoplasmic and intranuclear immunoreactivity especially in all phases of estrous cycle than control group. The figure was stained by H&E (bar 100 μ m). (B) Photomicrograph sections of uterus of ER β immunostaining in control and isoflavones cyclic female Wistar rats: isoflavones group (50 mg/kg/day) revealed positive intracytoplasmic and intranuclear immunostaining reaction in LE, GE and serosa (SE). However, control group showed less immunoreactivity to ER β in estrous phases. The figure was stained by H&E (bar 100 μ m).

this study, the potential estrogenic effects of isoflavones on ER α , ER β , and VEGF immunohistochemistry were assessed using estrogen-responsive tissues ovary and uterus.

Soy isoflavones administered group showed a significant reduction in FBW as well as BWG than control. These results were similar to previous results of Elsayed *et al.*, (2020). The reduction in body weight and BWG could be attributed to the appetite repression (Wade, 1975) that is caused by the hypothalamic estrogen stimulating action of isoflavones (Xu *et al.*, 2011). Furthermore, the estrogenic influence of isoflavones could regulate body fats and downgrade their leptin production, therefore, repressing appetite (Szkudelska *et al.*, 2000).

It was noticed that soy isoflavones significantly increased both the ovarian and uterine weights during all phases of estrous than control. This increment could be attributed to the increased number of ovarian follicles as well as

the observed hyperemia in the histopathological section. Moreover, the increase in the uterine weight represented by edema and water imbibitions in the stroma of isoflavones-treated uteri. This may be attributed to the estrogenic response of isoflavones that also stimulated endometrial proliferation and hyperplasia (Albertazzi and Sharma, 2005). Previous studies have shown similar results and confirmed the estrogenic response of isoflavones in reproductive tract (Rimoldi *et al.*, 2007; Teixeira *et al.*, 2019). On the other hand, Diel *et al.* (2006) showed that isoflavones did not elicit estrogenic effect or weight variation on reproductive tract. However, Bitto *et al.* (2010) reported that genistein aglycone might be useful for the management of endometrial hyperplasia in women.

Female rats administered soy isoflavones showed alterations in the regularity of the estrous cycle where 10 (62.5%) out of 16 females exhibited irregular cycles.

Table 3. Percentages of immunostained area (mean ± SEM) of ovarian and uterine ER α , ER β and VEGF.

| Parameters | Estrous phases | Control | Isoflavones |
|---------------------|----------------|--------------|---------------------------|
| Ovarian ER α | Proestrus | 37.02 ± 1.81 | 54.92 ± 1.49 ^a |
| | Estrus | 38.69 ± 1.98 | 51.74 ± 2.25 ^a |
| | Metestrus | 39.29 ± 1.79 | 52.93 ± 1.85 ^a |
| | Diestrus | 39.06 ± 1.73 | 52.48 ± 1.69 ^a |
| Uterine ER α | Proestrus | 31.64 ± 1.07 | 48.14 ± 1.29 ^a |
| | Estrus | 32.07 ± 0.95 | 48.57 ± 1.25 ^a |
| | Metestrus | 31.96 ± 0.98 | 46.58 ± 1.38 ^a |
| | Diestrus | 31.87 ± 1.15 | 46.76 ± 1.33 ^a |
| Ovarian ER β | Proestrus | 30.57 ± 1.46 | 41.65 ± 1.57 ^a |
| | Estrus | 33.62 ± 1.35 | 46.22 ± 1.87 ^a |
| | Metestrus | 31.38 ± 1.66 | 42.02 ± 1.22 ^a |
| | Diestrus | 31.10 ± 1.22 | 41.57 ± 1.42 ^a |
| Uterine ER β | Proestrus | 35.34 ± 0.92 | 49.02 ± 1.76 ^a |
| | Estrus | 37.53 ± 0.89 | 52.11 ± 1.73 ^a |
| | Metestrus | 36.12 ± 0.92 | 50.25 ± 1.72 ^a |
| | Diestrus | 37.18 ± 0.74 | 46.98 ± 1.24 ^a |
| Ovarian VEGF | Proestrus | 31.22 ± 1.70 | 48.36 ± 1.62 ^a |
| | Estrus | 33.42 ± 1.87 | 45.45 ± 2.53 ^a |
| | Metestrus | 29.33 ± 1.48 | 47.50 ± 1.80 ^a |
| | Diestrus | 29.74 ± 1.10 | 46.42 ± 1.65 ^a |
| Uterine VEGF | Proestrus | 31.69 ± 1.26 | 42.68 ± 1.75 ^a |
| | Estrus | 30.33 ± 1.37 | 40.62 ± 1.52 ^a |
| | Metestrus | 30.04 ± 1.47 | 37.86 ± 0.93 ^a |
| | Diestrus | 30.96 ± 1.61 | 39.73 ± 1.39 ^a |

^aAt the same raw indicates significance at $p < 0.001$

The most common findings were being; prolongation of estrus while shortening the diestrus phase of isoflavones administered group. Others have shown similar estrous cycle alterations in other model systems (Jefferson *et al.*, 2006). Estrogenic potency of isoflavones was reflected in marked changes in vaginal estrous cycle revealing alterations of estrous cyclicity (You *et al.*, 2002) as demonstrated by increased ovarian and uterine ERs ISAP in this study. Isoflavones, especially genistein are more selective to ER β due to their structural similarity to estrogen (Sirtori *et al.*, 2005). The pattern of estrous cyclicity is usually determined via the circulating level of estrogen and the existence of ERs in both ovarian and uterine tissues. The pattern of their expression could influence estrogen-responsive genes in a manner which is cell specific (Li, 1994). It seems that the disrupted estrous cycle may be attributed to the change in spatial ovarian and uterine ER β expression. The ER β is essential to the early-stage follicle growth and the interaction between the two ERs is required for the late stage of follicle growth (Couse *et al.*, 1997).

VEGF is expressed in LE, GE, CT stroma, v and M of uterus while in ovary it was expressed in stroma and corpus luteum with higher expression values in isoflavones administered group. This increment in VEGF could be accredited to the estrogenic potential of isoflavones displayed by the promoted uterine cellularity. Some studies displayed the change in expression of VEGF with disparities in ERs concentration (Bausero *et al.*, 1998; Hervé *et al.*, 2006). In any event, VEGF over production probably identifies blood vessels and its size and strongly suggests a role for VEGF in *in vivo* angiogenesis and microvascular hyperpermeability (Bausero *et al.*, 1998) manifested by edema that was observed in the current study. Moreover, the hyperexpression of VEGF could be involved in pathological situations, abnormal hyperpermeability, and dilated capillaries and increase the risk of uterine cancer (Bausero *et al.*, 1998; Zhang *et al.*, 2016). This suggests that isoflavones could predispose uterine neoplasia. These results are in disagreement with those of Niwa *et al.* (2000) who demonstrated the inhibitory effect of genistein and daidzein on endometrial carcinogenesis and attributed




Fig. 5. (A) Photomicrograph sections of ovary of VEGF immunostaining in control and isoflavones cyclic female Wistar rats: estrous phases of 50 mg/kg/day isoflavones group showed more intense positive intracytoplasmic immunoreactivity in all estrous phases. However, control group exhibited less immunoreactivity in VEGF receptors. The figure was stained by H&E (bar 50 µm). (B) Photomicrograph sections of uterus of VEGF immunostaining in control and isoflavone cyclic female Wistar rats: estrous phases of 50 mg/kg/day isoflavones group showed pronounced positive intracytoplasmic VEGF immunoreactive staining. Control group showed less VEGF immunoreactivity than 50 mg/kg/day isoflavones group. The figure was stained by H&E (bar 50 µm).

it to their antiestrogenic action and suppression of its downstream estrogen receptor response elements.

Taking together all the results, it was shown that soy isoflavones as SERM could increase both ERs subtypes. ER α mainly encountered the uterotrophic response as well as VEGF-induced vascular and permeability changes while ER β encountered cyclic patterns irregularity.

Conclusion

The present study showed the adverse effects of isoflavones on the reproductive pattern in cyclic female Wistar rats. Isoflavones induced reproductive cycle irregularities that are encountered by increased and altered ER β expression pattern. Moreover, proliferative changes were evident that were mediated by ER α expression, especially in uterus. Also, isoflavones up regulated VEGF expression in ER α expression dependent pattern that promoted angiogenesis and hyperpermeability in blood vessels that may

predisposes pathological conditions as neoplasia in uterus and ovary.

Author's contribution

D.H.E analyzed the data statistically and wrote the manuscript. S.A.H. and A.A.D. prepared the figures. A.M.E. revised the manuscript. H.M.A. and H.N.G performed the study and discussed the results.

Conflict of interest

All the authors declare that they have no competing interest.

References

- Abdelrazek, H.M.A., Mahmoud, M.M.A., Tag, H.M., Greish, S.M., Eltamany, D.A. and Soliman, M.T.A. 2019. Soy isoflavones ameliorate metabolic and immunological alterations of ovariectomy in female Wistar rats: antioxidant and estrogen sparing potential. *Oxid. Med. Cell. Longev.* 2019, 1–13.

- Adams, N.R. 1995. Detection of the effects of phytoestrogens on sheep and cattle. *J. Anim. Sci.* 73, 1509–1515.
- Albertazzi, P. and Sharma, S. 2005. Urogenital effects of selective estrogen receptor modulators: a systematic review. *Climacteric* 8, 214–220.
- Bausero, P., Cavaill , F., M duri, G., Freitas, S. and Perrot-Appianat, M. 1998. Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. *Angiogenesis* 2, 167–182.
- Bitto, A., Granese, R., Triolo, O., Villari, D., Maisano, D., Giordano, D., Altavilla, D., Marini, H., Adamo, E.B., Nicotina, P.A., Anna, R.D., and Squadrito, F. 2010. Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. *Phytomedicine* 17, 844–850.
- Couse, J.F., Lindzey, J., Grandien, K., Gustafsson, J.A. and Korach, K.S. 1997. Tissue distribution and quantitative analysis of estrogen receptor- α (ER α) and estrogen receptor- β (ER β) messenger ribonucleic acid in the wild-type and ER α -knockout mouse. *Endocrinology* 138, 4613–4621.
- da Silva Pacheco, S., Rondini, T.A., Bittencourt, J.C. and Fuzeti Elias, C. 2019. Neurons expressing estrogen receptor α differentially innervate the periaqueductal gray matter of female rats. *J. Chem. Neuroanat.* 97, 33–42.
- Danastas, K., Whittington, C.M., Dowland, S.N., Combes, V., Murphy, C.R. and Lindsay, L.A. 2019. Ovarian hyperstimulation reduces vascular endothelial growth factor—a during uterine receptivity. *Reprod. Sci.* 26, 259–268.
- Diel, P., Hertrampf, T., Seibel, J., Laudenschowsky, U., Kolba, S. and Vollmer, G. 2006. Combinatorial effects of the phytoestrogen genistein and of estradiol in uterus and liver of female Wistar rats. *J. Steroid. Biochem. Mol. Biol.* 102, 60–70.
- Elsayed, D.H., Abdelrazek, H.M.A., Eltamany, D.A., Ebaid, H.M. and El-Nahla, A.M. 2020. Effect of soy isoflavones on implantation losses in Wistar rat: implication of progesterone receptors, vascular endothelial growth factor and estradiol receptors alpha. *Iran. J. Vet. Res.* 21, 46.
- Franco, P.C., Sim es, R.S., Carbonel, A.A.F., Sasso, G.R.d.S., Florencio-Silva, R., Baracat, E.C., Gir o, M.B.C., Soares J nior, J.M. and Sim es, M.d.J. 2020. The influence of phytoestrogens or estrogens on the proliferation of the rat endocervical mucosa. *Rev. Assoc. Med. Bras.* 66, 174–179.
- Gaffer, G.G., Elgawish, R.A., Abdelrazek, H.M.A., Ebaid, H.M. and Tag, H.M. 2018. Dietary soy isoflavones during pregnancy suppressed the immune function in male offspring albino rats. *Toxicol. Rep.* 5, 296–301.
- Goldman, J.M., Murr, A.S. and Cooper, R.L. 2007. The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. *Birth. Defects. Res. B. Dev. Reprod. Toxicol.* 80, 84–97.
- Helmy, A., Emarah, H. and Abdelrazek, H. 2014. Estrogenic effect of soy phytoestrogens on the uterus of ovariectomized female rats. *Clin. Pharmacol. Biopharm.* 2, 7.
- Herv , M.A.J., Meduri, G., Petit, F.G., Domet, T.S., Lazennec, G., Mourah, S. and Perrot-Appianat, M. 2006. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. *J. Endocrinol.* 188, 91–99.
- Jari , I.,  ivanovi , J., Miler, M., Ajdzanovi , V., Blagojevi , D., Risti , N., Milo evi , V. and Nestorovi , N. 2018. Genistein and daidzein treatments differently affect uterine homeostasis in the ovary-intact middle-aged rats. *Toxicol. Appl. Pharmacol.* 339, 73–84.
- Jefferson, W.N., Padilla-Banks, E. and Newbold, R.R. 2006. Studies of the effects of neonatal exposure to genistein on the developing female reproductive system. *J. AOAC. Int.* 89, 1189–1196.
- Kallela, K., Heinonen, K. and Saloniemi, H. 1984. Plant oestrogens; the cause of decreased fertility in cows. a case report. *Nord. Vet. Med.* 36, 124–129.
- Kazi, A.A., Jones, J.M. and Koos, R.D. 2005. Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor α and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. *Mol. Endocrinol.* 19, 2006–2019.
- Kim, I. and Greenwald, G.S. 1987. Estrogen receptors in ovary and uterus of immature hamster and rat: effects of estrogens. *Endocrinol. Japonica.* 34, 45–53.
- Kuiper, G.G., Carlsson, B., Grandien, K., Enmark, E., H ggblad, J., Nilsson, S. and Gustafsson, J.A. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. *Endocrinology* 138, 863–870.
- Li, S. 1994. Relationship between cellular DNA synthesis, PCNA expression and sex steroid hormone receptor status in the developing mouse ovary, uterus and oviduct. *Histochemistry* 102, 405–413.
- Mc Rodrigues, G., Db Borges, B., Moreira, L.G.Q., Rossete,  .A.G. and de Castro Franca, S. 2018. Effects of estrogen-like plant compounds on the vaginal epithelium pituitary, adrenal glands, and uterus of rats. *Exp. Biol. Med. (Maywood).* 243, 1173–1184.
- Morito, K., Hirose, T., Kinjo, J., Hirakawa, T., Okawa, M., Nohara, T., Ogawa, S., Inoue, S., Muramatsu, M. and Masamune, Y. 2001. Interaction of phytoestrogens with estrogen receptors α and β . *Biol. Pharm. Bull.* 24, 351–356.
- Newbold, R.R., Jefferson, W.N., Grissom, S.F., Padilla-Banks, E., Snyder, R.J. and Lobenhofer, E.K. 2007. Developmental exposure to diethylstilbestrol alters

- uterine gene expression that may be associated with uterine neoplasia later in life. *Mol. Carcinog.* 46, 783–796.
- Nikaido, Y., Yoshizawa, K., Danbara, N., Tsujita-Kyutoku, M., Yuri, T., Uehara, N. and Tsubura, A. 2004. Effects of maternal xenoestrogen exposure on development of the reproductive tract and mammary gland in female CD-1 mouse offspring. *Reprod. Toxicol.* 18, 803–811.
- Niwa, H., Miyazaki, J. and Smith, A.G. 2000. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat. Genet.* 24, 372–376.
- Patel, S. 2018. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. *J. Steroid. Biochem. Mol. Biol.* 182, 27–36.
- Patisaul, H.B. 2017. Endocrine disruption by dietary phyto-oestrogens: impact on dimorphic sexual systems and behaviours. *Proc. Nutr. Soc.* 76, 130–144.
- Rajan, R.K., Kumar, S.S.M. and Balaji, B. 2017. Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. *Pharma. Biol.* 55, 242–251.
- Rimoldi, G., Christoffel, J., Seidlova-Wuttke, D., Jarry, H. and Wuttke, W. 2007. Effects of chronic genistein treatment in mammary gland, uterus, and vagina. *Environ. Health. Perspect.* 115, 62–68.
- Singletary, S.J., Kirsch, A.J., Watson, J., Karim, B.O., Huso, D.L., Hurn, P.D. and Murphy, S.J. 2005. Lack of correlation of vaginal impedance measurements with hormone levels in the rat. *J. Am. Assoc. Lab. Anim. Sci.* 44, 37–42.
- Sirtori, C.R., Arnoldi, A. and Johnson, S.K. 2005. Phytoestrogens: end of a tale? *Ann. Med.* 37, 423–438.
- Slaoui, M. and Fiette, L. 2011. Histopathology procedures: from tissue sampling to histopathological evaluation. *Methods. Mol. Biol.* 691, 69–82.
- Šošić-Jurjević, B., Lütjohann, D., Renko, K., Filipović, B., Radulović, N., Ajdžanović, V., Trifunović, S., Nestorović, N., Živanović, J., Stojanoski, M.M., Köhrle, J. and Milošević, V. 2019. The isoflavones genistein and daidzein increase hepatic concentration of thyroid hormones and affect cholesterol metabolism in middle-aged male rats. *J. Steroid. Biochem. Mol. Biol.* 190, 1–10.
- Stubert, J. and Gerber, B. 2009. Isoflavones—mechanism of action and impact on breast cancer risk. *Breast. Care.* 4, 22–29.
- Szkudelska, K., Nogowski, L. and Szkudelski, T. 2000. Genistein affects lipogenesis and lipolysis in isolated rat adipocytes. *J. Steroid. Biochem. Mol. Biol.* 75, 265–271.
- Teixeira, C.P., Florencio-Silva, R., Sasso, G.R.S., Carbonel, A.A.F., Simões, R.S. and Simões, M.J. 2019. Soy isoflavones protect against oxidative stress and diminish apoptosis in ovary of middle-aged female rats. *Gynecol. Endocrinol.* 35, 586–590.
- Terman, B.I., Dougher-Vermazen, M., Carrion, M.E., Dimitrov, D., Armellino, D.C., Gospodarowicz, D. and Böhlen, P. 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. *Biochem. Biophys. Res. Commun.* 187, 1579–1586.
- Tousen, Y., Umeki, M., Nakashima, Y., Ishimi, Y. and Ikegami, S. 2006. Effects of genistein, an isoflavone, on pregnancy outcome and organ weights of pregnant and lactating rats and development of their suckling pups. *J. Nutr. Sci. Vitaminol.* 52, 174–182.
- Ungar, Y., Osundahunsi, O.F. and Shimoni, E. 2003. Thermal stability of genistein and daidzein and its effect on their antioxidant activity. *J. Agric. Food Chem.* 51, 4394–4399.
- Wade, G.N. 1975. Some effects of ovarian hormones on food intake and body weight in female rats. *J. Comp. Physiol. Psychol.* 88, 183–193.
- Wang, A., Wei, J., Lu, C., Chen, H., Zhong, X., Lu, Y., Li, L., Huang, H., Dai, Z. and Han, L. 2019. Genistein suppresses psoriasis-related inflammation through a STAT3-NF- κ B-dependent mechanism in keratinocytes. *Int. Immunopharmacol.* 69, 270–278.
- Wang, H., Eriksson, H. and Sahlin, L. 2000. Estrogen receptors alpha and beta in the female reproductive tract of the rat during the estrous cycle. *Biol. Reprod.* 63, 1331–1340.
- Webb, P., Nguyen, P. and Kushner, P.J. 2003. Differential SERM effects on corepressor binding dictate ER α activity in vivo. *J. Biol. Chem.* 278, 6912–6920.
- Wu, G., Wei, Q., Yu, D. and Shi, F. 2019. Neonatal genistein exposure disrupts ovarian and uterine development in the mouse by inhibiting cellular proliferation. *J. Reprod. Dev.* 65, 7–17.
- Xu, B., Lovre, D. and Mauvais-Jarvis, F. 2017. The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: basic and clinical insights. *J. Diabetes Complications.* 31, 773–779.
- Xu, Y., Nedungadi, T.P., Zhu, L., Sobhani, N., Irani, B.G., Davis, K.E., Zhang, X., Zou, F., Gent, L.M., Hahner, L.D., Khan, S.A., Elias, C.F., Elmquist, J.K. and Clegg, D.J. 2011. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. *Cell. Metab.* 14, 453–465.
- You, L., Casanova, M., Bartolucci, E.J., Fryczynski, M.W., Dorman, D.C., Everitt, J.I., Gaido, K.W., Ross, S.M. and Heck, H.d.A. 2002. Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor. *Toxicol. Sci.* 66, 91–104.
- Zhang, J., Song, H., Lu, Y., Chen, H., Jiang, S. and Li, L. 2016. Effects of estradiol on VEGF and bFGF by Akt in endometrial cancer cells are mediated through the NF- κ B pathway. *Oncol. Rep.* 36, 705–714.